391 related articles for article (PubMed ID: 25959805)
1. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Jakubowska A; Szwiec M; Byrski T; Dębniak T; Górski B; Sopik V; Akbari MR; Sun P; Gronwald J; Narod SA; Lubiński J;
Lancet Oncol; 2015 Jun; 16(6):638-44. PubMed ID: 25959805
[TBL] [Abstract][Full Text] [Related]
2. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
3. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
4. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
5. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
[TBL] [Abstract][Full Text] [Related]
7. Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
[TBL] [Abstract][Full Text] [Related]
8. Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
Nguyen-Dumont T; Hammet F; Mahmoodi M; Tsimiklis H; Teo ZL; Li R; Pope BJ; Terry MB; Buys SS; Daly M; Hopper JL; Winship I; Goldgar DE; Park DJ; Southey MC
Breast Cancer Res Treat; 2015 Jan; 149(2):547-54. PubMed ID: 25575445
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.
Snyder C; Metcalfe K; Sopik V; Royer R; Zhang S; Narod SA; Akbari MR; Lynch HT
Breast Cancer Res Treat; 2015 Apr; 150(3):637-41. PubMed ID: 25794774
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
[TBL] [Abstract][Full Text] [Related]
12. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
13. Breast-cancer risk in families with mutations in PALB2.
Antoniou AC; Casadei S; Heikkinen T; Barrowdale D; Pylkäs K; Roberts J; Lee A; Subramanian D; De Leeneer K; Fostira F; Tomiak E; Neuhausen SL; Teo ZL; Khan S; Aittomäki K; Moilanen JS; Turnbull C; Seal S; Mannermaa A; Kallioniemi A; Lindeman GJ; Buys SS; Andrulis IL; Radice P; Tondini C; Manoukian S; Toland AE; Miron P; Weitzel JN; Domchek SM; Poppe B; Claes KB; Yannoukakos D; Concannon P; Bernstein JL; James PA; Easton DF; Goldgar DE; Hopper JL; Rahman N; Peterlongo P; Nevanlinna H; King MC; Couch FJ; Southey MC; Winqvist R; Foulkes WD; Tischkowitz M
N Engl J Med; 2014 Aug; 371(6):497-506. PubMed ID: 25099575
[TBL] [Abstract][Full Text] [Related]
14. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
[TBL] [Abstract][Full Text] [Related]
15. A PALB2 mutation associated with high risk of breast cancer.
Southey MC; Teo ZL; Dowty JG; Odefrey FA; Park DJ; Tischkowitz M; Sabbaghian N; Apicella C; Byrnes GB; Winship I; Baglietto L; Giles GG; Goldgar DE; Foulkes WD; Hopper JL;
Breast Cancer Res; 2010; 12(6):R109. PubMed ID: 21182766
[TBL] [Abstract][Full Text] [Related]
16. Tumour morphology predicts PALB2 germline mutation status.
Teo ZL; Provenzano E; Dite GS; Park DJ; Apicella C; Sawyer SD; James PA; Mitchell G; Trainer AH; Lindeman GJ; Shackleton K; Cicciarelli L; ; Buys SS; Andrulis IL; Mulligan AM; Glendon G; John EM; Terry MB; Daly M; Odefrey FA; Nguyen-Dumont T; Giles GG; Dowty JG; Winship I; Goldgar DE; Hopper JL; Southey MC
Br J Cancer; 2013 Jul; 109(1):154-63. PubMed ID: 23787919
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
18. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
19. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
20. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study.
Chen P; Liang J; Wang Z; Zhou X; Chen L; Li M; Xie D; Hu Z; Shen H; Wang H
Clin Cancer Res; 2008 Sep; 14(18):5931-7. PubMed ID: 18794107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]